Bern, Switzerland, Thursday, January 26, 2023 – CIS Pharma attends the first Swiss RNA Therapeutics Summit in Bern. The Summit brings together stakeholders in the field of RNA Therapeutics from academia, biotechnology, pharma, manufacturing, government, and regulatory bodies to join forces in this rapidly advancing field. Christoph Schäfer, CEO, is looking forward to learn more from industry leaders about the latest trends in RNA therapeutics and to discuss CIS Pharma’s linker technology for targeted delivery of oligonucleotides.

About CIS Pharma linker and carrier technology for targeted delivery of RNAi

RNA interference (RNAi) is a mechanism used to defend against external invasion. Oligo- and poly-nucleotide based RNAi therapeutics comprise a high clinical potential for unmet medical diseases and are seen as promising approach to combat a number of different indications including oncology, genetic disorders, auto-immune disorders, orphan diseases and viral infections.

Without a targeting technology, the therapeutics are predominantly metabolized by the liver. To prevent metabolization, the oligo-nucleotides are applied locally, limiting the clinical window for oligonucleotide therapies. Alternatively, targeted delivery to specific cells has to be developed to create novel therapies.

About CIS Pharma AG

CIS Pharma AG is an innovator in the life science industry. The company was founded in 1952 and is family owned. In our laboratories, we synthesize novel molecules, develop new biomaterials and create cutting-edge medical devices. Our mission is to improve the risk-benefit profile of therapeutics that are the standard of care, thereby improving patient’s experience and treatment outcome. Medical need, patient centricity and digital technology are key to our research and development programs. CIS Pharma is located in the region of Basel, Switzerland, one of the most successful life sciences locations in the world. For more information about the company, visit our website